- Home
- IMNN vs BIVI Comparison
IMNN vs BIVI Comparison
Compare IMNN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- BIVI
- Stock Information
- Founded
- IMNN 1982
- BIVI 2013
- Country
- IMNN United States
- BIVI United States
- Employees
- IMNN N/A
- BIVI N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- BIVI Health Care
- Exchange
- IMNN Nasdaq
- BIVI Nasdaq
- Market Cap
- IMNN 12.9M
- BIVI 14.2M
- IPO Year
- IMNN 1985
- BIVI N/A
- Fundamental
- Price
- IMNN $5.10
- BIVI $2.00
- Analyst Decision
- IMNN Buy
- BIVI
- Analyst Count
- IMNN 2
- BIVI 0
- Target Price
- IMNN $182.61
- BIVI N/A
- AVG Volume (30 Days)
- IMNN 160.1K
- BIVI 203.6K
- Earning Date
- IMNN 11-06-2025
- BIVI 11-12-2025
- Dividend Yield
- IMNN N/A
- BIVI N/A
- EPS Growth
- IMNN N/A
- BIVI N/A
- EPS
- IMNN N/A
- BIVI N/A
- Revenue
- IMNN N/A
- BIVI N/A
- Revenue This Year
- IMNN N/A
- BIVI N/A
- Revenue Next Year
- IMNN N/A
- BIVI N/A
- P/E Ratio
- IMNN N/A
- BIVI N/A
- Revenue Growth
- IMNN N/A
- BIVI N/A
- 52 Week Low
- IMNN $4.70
- BIVI $1.42
- 52 Week High
- IMNN $41.22
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- IMNN 41.04
- BIVI 49.22
- Support Level
- IMNN $4.91
- BIVI $1.81
- Resistance Level
- IMNN $5.39
- BIVI $2.04
- Average True Range (ATR)
- IMNN 0.24
- BIVI 0.13
- MACD
- IMNN 0.00
- BIVI 0.05
- Stochastic Oscillator
- IMNN 26.51
- BIVI 79.80
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.